Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial - Wu, Y L; Cheng, Y; Zhou, X (Lancet Oncol, 2017)
, et al.